Omeros (NASDAQ:OMER) Upgraded at StockNews.com

StockNews.com upgraded shares of Omeros (NASDAQ:OMER) from a sell rating to a hold rating in a research note issued to investors on Thursday morning.

Several other brokerages have also issued reports on OMER. Rodman & Renshaw initiated coverage on Omeros in a research note on Thursday, November 14th. They set a “buy” rating and a $9.00 price target for the company. D. Boral Capital reaffirmed a “buy” rating and set a $36.00 price target on shares of Omeros in a research note on Thursday, February 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of Omeros in a research note on Friday, January 17th. Cantor Fitzgerald reissued a “neutral” rating on shares of Omeros in a research note on Thursday, November 14th. Finally, RODMAN&RENSHAW raised Omeros to a “strong-buy” rating in a research note on Thursday, November 14th. Three research analysts have rated the stock with a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Omeros Price Performance

NASDAQ:OMER opened at $8.42 on Thursday. The business has a fifty day simple moving average of $8.80 and a two-hundred day simple moving average of $7.17. Omeros has a 1 year low of $2.61 and a 1 year high of $13.60. The company has a market capitalization of $487.94 million, a P/E ratio of -3.65 and a beta of 2.03.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Truvestments Capital LLC raised its position in Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC raised its position in Omeros by 79.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after purchasing an additional 1,972 shares during the last quarter. Quantbot Technologies LP bought a new position in Omeros during the 4th quarter valued at approximately $46,000. BNP Paribas Financial Markets raised its position in Omeros by 130.6% during the 3rd quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 7,016 shares during the last quarter. Finally, Picton Mahoney Asset Management raised its position in Omeros by 692.5% during the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 4,404 shares during the last quarter. Institutional investors own 48.79% of the company’s stock.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.